Technical Analysis for THAR - Tharimmune, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | -0.42% | |
BB Squeeze Ended | Range Expansion | -0.42% | |
Down 3 Days in a Row | Weakness | -0.42% | |
Down 4 Days in a Row | Weakness | -0.42% | |
Oversold Stochastic | Weakness | -0.42% | |
20 DMA Resistance | Bearish | -1.29% | |
Bollinger Band Squeeze | Range Contraction | -1.29% | |
Stochastic Reached Oversold | Weakness | -1.29% | |
Down 3 Days in a Row | Weakness | -1.29% | |
Oversold Stochastic | Weakness | -1.29% |
Alert | Time |
---|---|
2x Volume Pace | about 1 hour ago |
1.5x Volume Pace | about 1 hour ago |
3x Volume Pace | about 1 hour ago |
60 Minute Opening Range Breakdown | about 23 hours ago |
20 DMA Resistance | about 23 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Antibodies Autoimmune Disease Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Antibodies Autoimmune Disease Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.4725 |
52 Week Low | 0.3439 |
Average Volume | 249,216 |
200-Day Moving Average | 2.55 |
50-Day Moving Average | 0.40 |
20-Day Moving Average | 0.37 |
10-Day Moving Average | 0.38 |
Average True Range | 0.03 |
RSI (14) | 41.86 |
ADX | 9.5 |
+DI | 17.60 |
-DI | 17.11 |
Chandelier Exit (Long, 3 ATRs) | 0.35 |
Chandelier Exit (Short, 3 ATRs) | 0.44 |
Upper Bollinger Bands | 0.40 |
Lower Bollinger Band | 0.35 |
Percent B (%b) | 0.25 |
BandWidth | 13.93 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0005 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.40 | ||||
Resistance 3 (R3) | 0.40 | 0.39 | 0.39 | ||
Resistance 2 (R2) | 0.39 | 0.38 | 0.39 | 0.39 | |
Resistance 1 (R1) | 0.38 | 0.37 | 0.37 | 0.37 | 0.39 |
Pivot Point | 0.37 | 0.37 | 0.36 | 0.36 | 0.37 |
Support 1 (S1) | 0.35 | 0.36 | 0.35 | 0.35 | 0.34 |
Support 2 (S2) | 0.34 | 0.35 | 0.34 | 0.33 | |
Support 3 (S3) | 0.33 | 0.34 | 0.33 | ||
Support 4 (S4) | 0.33 |